Cargando…
Umbilical cord-derived CD362(+) mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy
BACKGROUND: Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071745/ https://www.ncbi.nlm.nih.gov/pubmed/32169108 http://dx.doi.org/10.1186/s13287-020-01624-8 |
_version_ | 1783506271868026880 |
---|---|
author | Horie, Shahd Masterson, Claire Brady, Jack Loftus, Paul Horan, Emma O’Flynn, Lisa Elliman, Steve Barry, Frank O’Brien, Timothy Laffey, John G. O’Toole, Daniel |
author_facet | Horie, Shahd Masterson, Claire Brady, Jack Loftus, Paul Horan, Emma O’Flynn, Lisa Elliman, Steve Barry, Frank O’Brien, Timothy Laffey, John G. O’Toole, Daniel |
author_sort | Horie, Shahd |
collection | PubMed |
description | BACKGROUND: Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored. METHODS: Adult male rats were subject to E. coli-induced pneumonia and administered CD362(+) umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with E. coli and randomized to receive heterogeneous BM or UC-hMSCs or CD362(+) UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362(+) UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0 h vs 6 h post-injury vs 6 h + 12 h) following E. coli installation. RESULTS: CD362(+) UC-hMSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362(+) UC-hMSCs recapitulated this efficacy, attenuating E. coli-induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362(+) UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from E. coli injury when delivered at 6 h + 12 h, following E. coli instillation. CONCLUSIONS: These translational studies demonstrated the efficacy of CD362(+) UC-hMSCs, where they decreased the severity of E. coli-induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the presence of antibiotic therapy, and could continue to provide benefit at later time points following E. coli injury. |
format | Online Article Text |
id | pubmed-7071745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70717452020-03-18 Umbilical cord-derived CD362(+) mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy Horie, Shahd Masterson, Claire Brady, Jack Loftus, Paul Horan, Emma O’Flynn, Lisa Elliman, Steve Barry, Frank O’Brien, Timothy Laffey, John G. O’Toole, Daniel Stem Cell Res Ther Research BACKGROUND: Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored. METHODS: Adult male rats were subject to E. coli-induced pneumonia and administered CD362(+) umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with E. coli and randomized to receive heterogeneous BM or UC-hMSCs or CD362(+) UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362(+) UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0 h vs 6 h post-injury vs 6 h + 12 h) following E. coli installation. RESULTS: CD362(+) UC-hMSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362(+) UC-hMSCs recapitulated this efficacy, attenuating E. coli-induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362(+) UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from E. coli injury when delivered at 6 h + 12 h, following E. coli instillation. CONCLUSIONS: These translational studies demonstrated the efficacy of CD362(+) UC-hMSCs, where they decreased the severity of E. coli-induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the presence of antibiotic therapy, and could continue to provide benefit at later time points following E. coli injury. BioMed Central 2020-03-13 /pmc/articles/PMC7071745/ /pubmed/32169108 http://dx.doi.org/10.1186/s13287-020-01624-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Horie, Shahd Masterson, Claire Brady, Jack Loftus, Paul Horan, Emma O’Flynn, Lisa Elliman, Steve Barry, Frank O’Brien, Timothy Laffey, John G. O’Toole, Daniel Umbilical cord-derived CD362(+) mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy |
title | Umbilical cord-derived CD362(+) mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy |
title_full | Umbilical cord-derived CD362(+) mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy |
title_fullStr | Umbilical cord-derived CD362(+) mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy |
title_full_unstemmed | Umbilical cord-derived CD362(+) mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy |
title_short | Umbilical cord-derived CD362(+) mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy |
title_sort | umbilical cord-derived cd362(+) mesenchymal stromal cells for e. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071745/ https://www.ncbi.nlm.nih.gov/pubmed/32169108 http://dx.doi.org/10.1186/s13287-020-01624-8 |
work_keys_str_mv | AT horieshahd umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy AT mastersonclaire umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy AT bradyjack umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy AT loftuspaul umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy AT horanemma umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy AT oflynnlisa umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy AT ellimansteve umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy AT barryfrank umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy AT obrientimothy umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy AT laffeyjohng umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy AT otooledaniel umbilicalcordderivedcd362mesenchymalstromalcellsforecolipneumoniaimpactofdoseregimenpassagecryopreservationandantibiotictherapy |